Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) traded down 4.9% during mid-day trading on Tuesday . The company traded as low as $10.46 and last traded at $10.47. 33,193 shares changed hands during trading, an increase of 439% from the average session volume of 6,157 shares. The stock had previously closed at $11.00.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the stock. Oppenheimer increased their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 20th.
Check Out Our Latest Report on PHAR
Pharming Group Price Performance
The company has a 50-day moving average of $10.30 and a 200-day moving average of $9.39. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.00 and a current ratio of 2.76. The firm has a market capitalization of $724.52 million, a price-to-earnings ratio of -53.25 and a beta of 0.02.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The company had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. As a group, research analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
